Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

被引:96
|
作者
Achinger-Kawecka, Joanna [1 ,2 ]
Valdes-Mora, Fatima [1 ,2 ]
Luu, Phuc-Loi [1 ,2 ]
Giles, Katherine A. [1 ]
Caldon, C. Elizabeth [3 ]
Qu, Wenjia [1 ]
Nair, Shalima [1 ]
Soto, Sebastian [1 ]
Locke, Warwick J. [1 ]
Yeo-Teh, Nicole S. [1 ]
Gould, Cathryn M. [1 ]
Du, Qian [1 ]
Smith, Grady C. [1 ]
Ramos, Irene R. [4 ]
Fernandez, Kristine F. [3 ]
Hoon, Dave S. [4 ]
Gee, Julia M. W. [5 ]
Stirzaker, Clare [1 ,2 ]
Clark, Susan J. [1 ,2 ]
机构
[1] Garvan Inst Med Res, Epigenet Res Lab, Genom & Epigenet Theme, Sydney, NSW 2010, Australia
[2] UNSW Sydney, St Vincents Clin Sch, Fac Med, Sydney, NSW 2010, Australia
[3] Kinghorn Canc Ctr, Canc Theme, Sydney, NSW 2010, Australia
[4] John Wayne Canc Inst, Dept Translat Mol Med, Santa Monica, CA USA
[5] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Breast Canc Mol Pharmacol Grp, Cardiff CF10 3NB, Wales
基金
英国医学研究理事会;
关键词
DIFFERENTIAL EXPRESSION ANALYSIS; GENE-EXPRESSION; GENOME; ORGANIZATION; TAMOXIFEN; DOMAINS; REORGANIZATION; DISRUPTION; ACTIVATION; PRINCIPLES;
D O I
10.1038/s41467-019-14098-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer.
引用
收藏
页数:17
相关论文
共 12 条
  • [1] Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer
    Pathiraja, Thushangi N.
    Nayak, Shweta R.
    Xi, Yuanxin
    Jiang, Shiming
    Garee, Jason P.
    Edwards, Dean P.
    Lee, Adrian V.
    Chen, Jian
    Shea, Martin J.
    Santen, Richard J.
    Gannon, Frank
    Kangaspeska, Sara
    Jelinek, Jaroslav
    Issa, Jean-Pierre J.
    Richer, Jennifer K.
    Elias, Anthony
    McIlroy, Marie
    Young, Leonie S.
    Davidson, Nancy E.
    Schiff, Rachel
    Li, Wei
    Oesterreich, Steffi
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (229)
  • [2] The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer
    Achinger-Kawecka, Joanna
    Stirzaker, Clare
    Portman, Neil
    Campbell, Elyssa
    Chia, Kee-Ming
    Du, Qian
    Laven-Law, Geraldine
    Nair, Shalima S.
    Yong, Aliza
    Wilkinson, Ashleigh
    Clifton, Samuel
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Song, Jenny
    Khoury, Amanda
    Meyer, Braydon
    Chen, Wenhan
    Pidsley, Ruth
    Qu, Wenjia
    Gee, Julia M. W.
    Schmitt, Anthony
    Wong, Emily S.
    Hickey, Theresa E.
    Lim, Elgene
    Clark, Susan J.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2024, 31 (03) : 498 - 512
  • [3] Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer
    Dimitrakopoulos, Foteinos-Ioannis
    Kottorou, Anastasia
    Tzezou, Aspasia
    CANCER LETTERS, 2021, 517 : 55 - 65
  • [4] The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells
    Yang, Yini
    Choppavarapu, Lavanya
    Fang, Kun
    Naeini, Alireza S.
    Nosirov, Bakhtiyor
    Li, Jingwei
    Yang, Ke
    He, Zhijing
    Zhou, Yufan
    Schiff, Rachel
    Li, Rong
    Hu, Yanfen
    Wang, Junbai
    Jin, Victor X.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2020, 1863 (11):
  • [5] Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
    Liu, Xi-Yu
    Ma, Ding
    Xu, Xiao-En
    Jin, Xi
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    THERANOSTICS, 2018, 8 (22): : 6386 - 6399
  • [6] Reorganization of 3D chromatin architecture in doxorubicin-resistant breast cancer cells
    Wang, Xuelong
    Yan, Jizhou
    Ye, Zhao
    Zhang, Zhiqiang
    Wang, Sheng
    Hao, Shuang
    Shen, Baiyong
    Wei, Gang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [7] Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
    Guest, Stephanie K.
    Ribas, Ricardo
    Pancholi, Sunil
    Nikitorowicz-Buniak, Joanna
    Simigdala, Nikiana
    Dowsett, Mitch
    Johnston, Stephen R.
    Martin, Lesley-Ann
    PLOS ONE, 2016, 11 (06):
  • [8] Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance
    Zhou, Yufan
    Gerrard, Diana L.
    Wang, Junbai
    Li, Tian
    Yang, Yini
    Fritz, Andrew J.
    Rajendran, Mahitha
    Fu, Xiaoyong
    Schiff, Rachel
    Lin, Shili
    Frietze, Seth
    Jin, Victor X.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [9] AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
    Ribas, Ricardo
    Pancholi, Sunil
    Guest, Stephanie K.
    Marangoni, Elisabetta
    Gao, Qiong
    Thuleau, Aurelie
    Simigdala, Nikiana
    Polanska, Urszula M.
    Campbell, Hayley
    Rani, Aradhana
    Liccardi, Gianmaria
    Johnston, Stephen
    Davies, Barry R.
    Dowsett, Mitch
    Martin, Lesley-Ann
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (09) : 2035 - 2048
  • [10] Recurrent mutations at estrogen receptor binding sites alter chromatin topology and distal gene expression in breast cancer
    Yang, Jiekun
    Wei, Xiaolong
    Tufan, Turan
    Kuscu, Cem
    Unlu, Hayrunnisa
    Farooq, Saadia
    Demirtas, Elif
    Paschal, Bryce M.
    Adli, Mazhar
    GENOME BIOLOGY, 2018, 19